Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer
Journal
Lung Cancer
Journal Volume
129
Pages
110-111
Date Issued
2019
Author(s)
Lin Y.-T.
SDGs
Other Subjects
epidermal growth factor receptor; gefitinib; glucocorticoid; osimertinib; acrylamide derivative; aniline derivative; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; adult; algorithm of drug causality for epidermal necrolysis score; blister; cancer recurrence; cancer staging; case report; clinical article; computer assisted tomography; dermatitis; disease severity; drug withdrawal; EGFR gene; epiphora; face injury; female; follow up; gene mutation; genital injury; histopathology; human; human tissue; in vitro study; Letter; limb injury; lung adenocarcinoma; medical history; middle aged; mouth ulcer; priority journal; rash; scoring system; skin biopsy; Stevens Johnson syndrome; wedge resection; wound care; adverse drug reaction; genetics; lacrimal fluid; lung tumor; mutation; non small cell lung cancer; pathology; Stevens Johnson syndrome; ulcer; Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Stevens-Johnson Syndrome; Tears; Ulcer
Publisher
Elsevier Ireland Ltd
Type
letter